Online citations, reference lists, and bibliographies.
← Back to Search

A Randomized, Double-blind Study Comparing The Efficacy And Safety Of Trazodone Once-a-day And Venlafaxine Extended-release For The Treatment Of Patients With Major Depressive Disorder

A. Fagiolini, U. Albert, L. Ferrando, E. Herman, C. Muntean, E. Pálová, A. Cattaneo, A. Comandini, G. Di Dato, G. Di Loreto, L. Olivieri, E. Salvatori, S. Tongiani, S. Kasper
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Supplemental Digital Content is available in the text. This double-blind, randomized study evaluated the efficacy and safety of trazodone OAD (once-a-day) in comparison with venlafaxine XR (extended-release) in 324 patients (166 trazodone and 158 venlafaxine) with major depressive disorder (MDD). The primary efficacy endpoint was the mean change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) at week 8. Both treatments were effective in reducing the HAM-D-17 total score at week 8 vs. baseline (intent-to-treat: trazodone –12.9, venlafaxine –14.7; per protocol: trazodone –15.4, venlafaxine –16.4). Patients in the venlafaxine group achieved better results after 8 weeks, whereas the trazodone group achieved a statistically significant reduction in HAM-D-17 following only 7 days of treatment. The most frequent adverse events (AEs) were dizziness and somnolence in the trazodone group, and nausea and headache in the venlafaxine group. Most AEs were mild-to-moderate in severity. This study confirmed that both venlafaxine XR and trazodone OAD may represent a valid treatment option for patients with MDD.
This paper references
10.1097/00004714-199404000-00003
A comparison of venlafaxine, trazodone, and placebo in major depression.
L. Cunningham (1994)
Note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96)
Committee for Proprietary Medicinal Products (1998)
10.1001/ARCHINTE.160.14.2101
Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence.
M. Dimatteo (2000)
10.5691/JJB.27.S96
Points to consider on switching between superiority and non-inferiority.
H. Nishiyama (2001)
10.1016/S0149-2918(01)80109-0
A systematic review of the associations between dose regimens and medication compliance.
A. Claxton (2001)
10.1055/S-2003-43052
Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity.
H. Sauer (2003)
Efficacy and safety of venlafaxine ER vs
H Sauer (2003)
10.1016/S0165-0327(02)00300-2
Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis.
A. Yıldız (2004)
Rates of study completion with single vs
A Yildiz (2004)
10.4088/JCP.V66N0210
Continuity is the main challenge in treating major depressive disorder in psychiatric care.
T. Melartin (2005)
10.1185/030079905X53243
A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder
S. Kasper (2005)
[Trazodone and venlafaxine in treatment of depressive disorders].
A. Florkowski (2005)
Florkowski (2005)
10.1176/APPI.AJP.163.1.28
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
M. Trivedi (2006)
10.1371/journal.pmed.0030442
Projections of Global Mortality and Burden of Disease from 2002 to 2030
C. Mathers (2006)
10.1185/030079906X121039
A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder
C. Munizza (2006)
10.1097/01.mlr.0000204287.82701.9b
Methods for Evaluating Patient Adherence to Antidepressant Therapy: A Real-World Comparison of Adherence and Economic Outcomes
C. Cantrell (2006)
STAR*D Study Team
MH Trivedi (2006)
10.1097/01.mlr.0000254574.23418.f6
Adherence to Antidepressant Treatment Among Privately Insured Patients Diagnosed With Depression
A. Akincigil (2007)
10.1136/bmj.39197.619190.80
Onset of action of antidepressants
A. Tylee (2007)
10.4088/JCP.V69N0610
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.
R. Machado-Vieira (2008)
10.31887/dcns.2008.10.3/dnutt
Sleep disorders as core symptoms of depression
D. Nutt (2008)
10.1007/978-1-59745-387-5_2
Rating Scales for Depression
C. Cusin (2009)
Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.
D. Sheehan (2009)
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
D. Sheehan (2009)
10.1017/S1092852900024020
Mechanism of Action of Trazodone: a Multifunctional Drug
S. Stahl (2009)
10.1124/jpet.110.169417
Sustained Administration of Trazodone Enhances Serotonergic Neurotransmission: In Vivo Electrophysiological Study in the Rat Brain
R. Ghanbari (2010)
10.1007/978-1-59745-387-5
Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health
L. Baer (2010)
10.4088/JCP.9058se1c.04gry
Major depressive disorder treatment guidelines in America and Europe.
J. Davidson (2010)
10.1176/appi.ajp.2009.09111601
Born to be criminal? What to make of early biological risk factors for criminal behavior.
P. Sterzer (2010)
Practice guideline for the treatment of patients with major depressive disorder: third edition
AJ Gelenberg (2010)
10.1037/e517532013-004
Depression: a global public health concern
M. Marcus (2012)
10.1007/s40263-012-0010-5
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
A. Fagiolini (2012)
World Health Organization Department of Mental Health and Substance Abuse
M Marcus (2012)
10.1007/s00228-013-1582-9
Risk factors for non-adherence to antidepressant treatment in patients with mood disorders
C. De las Cuevas (2013)
10.2147/NDT.S39544
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
C. Katona (2014)
Adherence to Antidepressant Therapy : Sociodemographic Factor Wise Distribution
P. Alekhya (2015)
10.4172/2167-1044.1000175
Treatment and Disease Related Factors Affecting Non-adherence among Patients on Long Term Therapy of Antidepressants
P. Alekhya (2015)
10.2147/TCRM.S55313
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
Marc Kelliny (2015)
Kelliny (2015)
10.20900/jpbs.20160010
Analysis of Influencing Factors of Medication Compliance in Discharged Depressive Patients and Recurrence Situation
Yong Cheng (2016)
10.1016/j.jad.2015.12.029
Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review.
Siew Ching Ho (2016)
Cheng (2016)
10.1021/acschemneuro.7b00175
Proneurogenic Effects of Trazodone in Murine and Human Neural Progenitor Cells.
V. Bortolotto (2017)
10.1016/S0140-6736(17)32802-7
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
A. Cipriani (2018)
10.1159/000492079
Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
E. Češková (2018)
10.1371/journal.pone.0222855
Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and α1-adrenoceptor antagonism
A. Montalbano (2019)
Alekhya
Sheehan
Sheehan
Alekhya



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar